Crucef 1000mg/125mg Injection
Marketer
Aronex Life Sciences Pvt Ltd
Salt Composition
Ceftriaxone (1000mg) + Tazobactum (125mg)
Overview Crucef 1000mg/125mg Injection
Cefixime and Sulbactam 1000mg/125mg Injection is a dual-action antibiotic used to combat diverse bacterial infections. This medication inhibits bacterial proliferation, thus curbing infection spread. Administration must be under a physician's guidance; strict adherence to the prescribed dosage schedule is crucial. Complete the entire treatment course, even with symptom improvement, as premature cessation may compromise efficacy. Potential side effects include nausea, vomiting, diarrhea, and dyspepsia. Escalating side effects necessitate immediate medical consultation. Seek urgent medical attention for allergic reactions like rashes, itching, swelling, or respiratory distress. Inform your physician of all current medications, including those for pre-existing conditions, prior to commencing treatment. Pregnant or lactating individuals should consult their doctor before use. Alcohol consumption should be avoided due to the potential for increased drowsiness. While generally not impairing driving ability, refrain from driving if experiencing somnolence or dizziness. Adequate rest, a nutritious diet, and sufficient hydration are recommended for optimal recovery. Your doctor might order blood tests and other assessments to monitor the medicine's impact.
Primary Ingredients of Crucef 1000mg/125mg Injection
No text provided. Please provide the text you wish me to rephrase.
Uses of Crucef 1000mg/125mg Injection
Infections caused by bacteria
Major Benefits of Crucef 1000mg/125mg Injection:
Administering this medication will be done by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Crucef 1000mg/125mg Injection:
- Diarrhea
- Increased liver enzymes
- Allergic reaction
- Rash
How to use Crucef 1000mg/125mg Injection:
The medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
How Crucef 1000mg/125mg Injection works:
Ceftriaxone/Tazobactum 1000mg/125mg (Crucef) injection unites two active agents. Ceftriaxone, an antibiotic, disrupts bacterial cell wall synthesis, hindering bacterial survival. Tazobactum, a beta-lactamase inhibitor, counters bacterial resistance mechanisms, thereby augmenting Ceftriaxone's effectiveness.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse reactions from co-administering alcohol and Crucef 1000mg/125mg Injection.
PregnancySAFE IF PRESCRIBED
The injectable formulation of Crucef (1000mg/125mg) is typically deemed safe for pregnant individuals. Preclinical trials using animal models revealed minimal or no negative impacts on fetal development; nonetheless, clinical data from human subjects remain scarce.
Breast feedingCAUTION
Administering Crucef 1000mg/125mg Injection to breastfeeding mothers requires careful consideration. Lactation should be temporarily discontinued throughout the mother's treatment course and until the medication is fully cleared from her system.
DrivingUNSAFE
Administering Crucef 1000mg/125mg Injection can induce drowsiness, blurred vision, and dizziness. Refrain from operating a vehicle should these effects manifest.
KidneyCONSULT YOUR DOCTOR
Data on Crucef 1000mg/125mg Injection use in individuals with renal impairment is scarce. Physician consultation is advised.
LiverCAUTION
Patients with severe hepatic impairment should receive Crucef 1000mg/125mg Injection with close monitoring; dosage modification may be necessary. Consult a physician for guidance. Dosage alteration for Crucef 1000mg/125mg Injection is unnecessary in individuals exhibiting mild or moderate liver dysfunction.
What if you forget to take Crucef 1000mg/125mg Injection :
Should you inadvertently omit a scheduled dose of Crucef 1000mg/125mg Injection, seek immediate medical advice.
Facts to Know About Crucef 1000mg/125mg Injection
| Label | Value |
|---|---|
| Potential for Dependence | None. |
| Type of Medication | Antimicrobial agents |
3,018 People bought this recently